European external quality control study on the competence of laboratories to recognize rare sequence variants resulting in unusual genotyping results.

BACKGROUND Depending on the method used, rare sequence variants adjacent to the single nucleotide polymorphism (SNP) of interest may cause unusual or erroneous genotyping results. Because such rare variants are known for many genes commonly tested in diagnostic laboratories, we organized a proficiency study to assess their influence on the accuracy of reported laboratory results. METHODS Four external quality control materials were processed and sent to 283 laboratories through 3 EQA organizers for analysis of the prothrombin 20210G>A mutation. Two of these quality control materials contained sequence variants introduced by site-directed mutagenesis. RESULTS One hundred eighty-nine laboratories participated in the study. When samples gave a usual result with the method applied, the error rate was 5.1%. Detailed analysis showed that more than 70% of the failures were reported from only 9 laboratories. Allele-specific amplification-based PCR had a much higher error rate than other methods (18.3% vs 2.9%). The variants 20209C>T and [20175T>G; 20179_20180delAC] resulted in unusual genotyping results in 67 and 85 laboratories, respectively. Eighty-three (54.6%) of these unusual results were not recognized, 32 (21.1%) were attributed to technical issues, and only 37 (24.3%) were recognized as another sequence variant. CONCLUSIONS Our findings revealed that some of the participating laboratories were not able to recognize and correctly interpret unusual genotyping results caused by rare SNPs. Our study indicates that the majority of the failures could be avoided by improved training and careful selection and validation of the methods applied.

[1]  N. Key,et al.  Clinical and laboratory management of the prothrombin G20210A mutation. , 2009, Archives of pathology & laboratory medicine.

[2]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[3]  P. Ahmad-Nejad,et al.  Improvement of technical and analytical performance in DNA sequencing by external quality assessment-based molecular training. , 2006, Clinical Chemistry.

[4]  H. H. A. G. M. VAN DER PUTTEN,et al.  Functional analysis of two prothrombin 3′‐untranslated region variants: the C20209T variant, mainly found among African‐Americans, and the C20209A variant , 2006, Journal of thrombosis and haemostasis : JTH.

[5]  P. Ahmad-Nejad,et al.  Methodologic European external quality assurance for DNA sequencing: the EQUALseq program. , 2006, Clinical chemistry.

[6]  T. Clench,et al.  Rapid detection of the prothrombin C20209T transition by light cycler analysis , 2005, Thrombosis and Haemostasis.

[7]  J. Decker,et al.  Mutation screening for the prothrombin variant G20210A by melting point analysis with the Light Cycler system: atypical results, detection of the variant C20209T and possible clinical implications. , 2005, Clinical and laboratory haematology.

[8]  Elaine Lyon,et al.  Developing a Sustainable Process to Provide Quality Control Materials for Genetic Testing , 2005, Genetics in Medicine.

[9]  M. Mahadevan,et al.  Factor V null mutation affecting the Roche LightCycler factor V Leiden assay. , 2005, Clinical chemistry.

[10]  A. Gressner,et al.  Atypical melting curve resulting from genetic variation in the 3' untranslated region at position 20218 in the prothrombin gene analyzed with the LightCycler factor II (prothrombin) G20210A assay. , 2005, Clinical chemistry.

[11]  E. Lyon.  Discovering rare variants by use of melting temperature shifts seen in melting curve analysis. , 2005, Clinical chemistry.

[12]  F. Peyvandi,et al.  Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. , 2005, Clinical chemistry.

[13]  W. Grody,et al.  Technical standards and guidelines: Venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing): A disease-specific supplement to the standards and guidelines for clinical genetics laboratories , 2005, Genetics in Medicine.

[14]  E. Lyon,et al.  Distinguishing different DNA heterozygotes by high-resolution melting. , 2005, Clinical chemistry.

[15]  S. Kitchen,et al.  Multilaboratory Testing in Thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program , 2005, Seminars in thrombosis and hemostasis.

[16]  Elaine Lyon,et al.  Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. , 2004, Clinical chemistry.

[17]  J. Zehnder,et al.  Prothrombin gene variants in non-Caucasians with fetal loss and intrauterine growth retardation. , 2003, The Journal of molecular diagnostics : JMD.

[18]  P. Mannucci,et al.  Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern , 2002, Thrombosis and Haemostasis.

[19]  K. Kottke-Marchant,et al.  Detection of a Novel Point Mutation of the Prothrombin Gene at Position 20209 , 2002, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[20]  A. Gressner,et al.  An unusual melting curve profile in LightCycler multiplex genotyping of the hemochromatosis H63D/C282Y gene mutations. , 2001, Clinical biochemistry.

[21]  P. Lohse,et al.  Fluorescence-based detection of the CETP TaqIB polymorphism: false positives with the TaqMan-based exonuclease assay attributable to a previously unknown gene variant. , 2001, Clinical chemistry.

[22]  K. Wielckens,et al.  A Novel Point Mutation in the 3’ Region of the Prothrombin Gene at Position 20221 in a Lebanese/Syrian Family , 2001, Thrombosis and Haemostasis.

[23]  M. Neumaier,et al.  Experiences with External Quality Assessment (EQA) in Molecular Diagnostics in Clinical Laboratories in Germany , 2000, Clinical chemistry and laboratory medicine.

[24]  R. Hegele,et al.  Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis , 1999, Nature Genetics.

[25]  Lyondagger,et al.  Detection and Identification of Base Alterations Within the Region of Factor V Leiden by Fluorescent Melting Curves. , 1998, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[26]  B. Bruggeman,et al.  Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin). , 1998, Clinical chemistry.

[27]  C. Wittwer,et al.  Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. , 1997, Clinical chemistry.

[28]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[29]  P. Corbisier,et al.  Certification of reference materials for detection of the human prothrombin gene G20210A sequence variant , 2008, Clinical chemistry and laboratory medicine.

[30]  P. Reitsma,et al.  Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation , 2005, Clinical chemistry and laboratory medicine.